Hunting a cure, Spark reports steady progress on hemophilia B gene therapy as Pfizer preps for pivotal handoff – Endpoints News
Endpoints News |
Hunting a cure, Spark reports steady progress on hemophilia B gene therapy as Pfizer preps for pivotal handoff
Endpoints News After some fine tuning on the manufacturing side, Spark Therapeutics $ONCE says it's racked up a new round of promising results for its Phase I/II study of a groundbreaking new gene therapy that aims to cure hemophilia B. And the biotech is prepping a … Spark's gene therapy SPK-9001 shows treatment benefit in hemophilia B study Spark/Pfizer eye phase 3 trial of haemophilia B gene therapy More encouraging data for Spark and Pfizer's potential haemophilia B cure |
